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Aim: To show our preliminary experience in using TrueBeam with RapidArc technology and
FFF  beam for stereotactic re-irradiation of nasopharyngeal carcinoma.
Background: Thanks to new advanced techniques, as well as intensity modulated radiation
therapy, it is possible to approach head and neck recurrences in selected patients. Volumet-
ric  Modulated Arc Therapy (VMAT) in its RapidArc® format, permits to reduce signiﬁcantly
the  time to deliver complex intensity modulated plans, allowing to treat hypofractionated
regimes within a few minutes. With TrueBeam it is possible to perform photon beams with-
out  usage of the ﬂattening ﬁlter. It seems possible to expect a reduction of out-of-ﬁeld dose
when ﬂattening ﬁlter free (FFF) beams are used. While research into the physics domain for
FFF  beams is increasing, there are very few clinical data where FFF beams are applied in
clinical practice.
Materials and methods: We  present here the cases of 4 patients with local or regional
recurrence of nasopharyngeal carcinoma. All patients were treated using TrueBeam with
RapidArc technology and FFF beam for stereotactic hypofractionated re-irradiation.
Results: All patients concluded SBRT and showed good tolerability. During follow-up,
complete response at imaging evaluation (PET and/or MRI) for all treated patients was
documented.
Conclusions: Our preliminary experience using TrueBeam with RapidArc technology and FFFbeam for stereotactic hypofractionated re-irradiation of nasopharyngeal carcinoma was safe
and  effective in all 4 treated patients. Longer follow-up and a larger population of study is
needed to conﬁrm these promising results.
and C
in head and neck cancer patients; it also represents the most© 2012 Greater Pol
1.  BackgroundSystemic therapy is increasing survival in several subsets of
patients with head and neck cancer. Locoregional recurrence
∗ Corresponding author. Tel.: +39 0282248522; fax: +39 0282248509.
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1507-1367/$ – see front matter © 2012 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2012.07.012ancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
remains the predominant pattern of failure after treatmentscommon cause of death.1 Thus, local reirradiation is consid-
ered as a possible treatment option in case of recurrence in
the site of disease.
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Radiation retreatment is a problematic issue to resolve in
linical practice: it requires knowledge on the possibility of
nforeseen toxicity risks in healthy tissue. “Dose sculpting”
n active tumor with IMRT  is a helpful approach to min-
mize the radiation dose to previously irradiated tissues.2
mage-guided radiation therapy (IGRT) reduces repositioning
rrors and is used to monitor the treatment region and/or
o adapt dose distribution to the possibly changing target
nd organs at risk during radiotherapy.3 Recently, two new
echnological platforms have been made available to clinical
ractice. Firstly, Volumetric Modulated Arc Therapy (VMAT) in
ts RapidArc® format permits to reduce signiﬁcantly the time
eeded to deliver complex intensity modulated plans, allow-
ng to treat hypofractionated regimes within a few minutes.4
econdly, there has been increasing attention on the clinical
se of linear accelerators (LINAC) with photon beams gen-
rated without the usage of a ﬂattening ﬁlter.5–8 It seems
ossible to expect a reduction of out of-ﬁeld dose when ﬂat-
ening ﬁlter free (FFF) beams are used.33–36 This is mainly due
o reduced head scatter and residual electron contamination.
FF beams should, therefore, lead to reduced peripheral doses
nd patients may beneﬁt by decreased exposure of normal
issue to scattered doses outside the ﬁeld. Removal of the
attening ﬁlter implies also the possibility to deliver treat-
ents with higher dose rates, up to the factor 4 at 10 MV,
nd with a much higher dose per pulse. This, beside further
mproving time efﬁciency for delivery, might have subsequent
otential radiobiologic implications still unclear and deserv-
ng dedicated investigations. While research into the physics
omain for FFF beams is increasing, there are very few clin-
cal data where FFF beams are applied in clinical practice,32
articularly in stereotactic hypofractionated head and neck
e-treatments.
. Aim
e  present herein our preliminary experience in 4 patients
sing TrueBeam with RapidArc technology and FFF beam used
or stereotactic hypofractionated re-irradiation on local or
egional recurrence of nasopharyngeal carcinoma.
.  Materials  and  methods
rueBeamTM is a new LINAC designed to deliver ﬂattened,
s well as ﬂattening ﬁlter-free (FFF) photon beams. In
rueBeamTM, many  key elements including the waveguide
ystem, carousel assembly, beam generation, and monitor-
ng control system differ from the preceding LINAC series
s described in.9 All patients were treated with RapidArc®
sing 10 MV  FFF beams. The maximum dose rate enabled for
FF beams was 2400 MU/min for 10 MV. RapidArc® plans were
ndividually designed using full or partial single or multiple
rcs chosen to obtain the best adherence to planning objec-
ives for each patient.10 Treatment was delivered in 5 fractions
n 3 patients with recurrence in nasopharynx region and in
8 fractions in one patient with lymph node relapse, both
ver consecutive working days. Treatment delivery included
tereotactic frame localization and CBCT in the ﬁrst session
iming at a preliminary isocentre positioning while for thetherapy 1 7 ( 2 0 1 2 ) 262–268 263
following fractions, patient set-up was done by means of
a daily CBCT image  guidance with eventual on-line couch
adjustment at each fraction. Image  matching was performed
on bones and, when visible, on tumors and other soft tis-
sue structures. Clinical evaluations were planned on the ﬁrst
day of treatment, before radiation FFF session (visit 0); visit
1 in the course of the treatment; visit 2 at the end of the
last session; visit 3 within 60–90 days from the end of the
treatment. Unscheduled visits could be performed if neces-
sary. Acute radiation induced toxicities were scored according
to NCI Common Terminology Criteria for Adverse Events
(CTCAE version 3.0).11 A ﬁrst assessment of treatment out-
come, although obviously very early, was made at ﬁrst and
second follow up visits and are reported in terms of degree of
response.
3.1.  Case  1
Female patient, 41 years old. No other important concomi-
tant diseases were recorded in anamnesis. In July 2007, a
diagnosis of G2 carcinoma was made after a nasopharyngeal
biopsy. Concomitant presence of neoplastic cells at needle
aspiration exam in lateral right lymph node enlargement was
conﬁrmed. A cisplatin and 5-FU-based chemotherapy regi-
men was administered for two cycles and a partial response
was shown at MRI after 2 months. A subsequent concomi-
tant radiochemotherapy was performed, delivering 56 Gy by
means of external beam radiotherapy to the whole neck and
a boost by brachytherapy with doses of 9 Gy in 3 fractions.
In 2009, CT detected local failure in the left nasopharyngeal
region during follow-up. A biopsy conﬁrmed the recurrence of
nasopharyngeal Grade 3 carcinoma. Taxotere chemotherapy
was administered for 6 cycles with further local progression
shown on CT with contrast enhancement. In June 2010, a
PET/CT conﬁrmed the local failure with an exclusive FDG
pathologic accumulation in the left region of the nasophar-
ynx. In August 2010, Cetuximab was administered as salvage
therapy. A CT for re-evaluation four months later showed fur-
ther local progression of disease on the left side. In March
2011, the patient was referred to our Department of Radio-
therapy and Radiosurgery where it was decided to re-irradiate
the patient. PET/CT and MRI were used as imaging tools for
image fusion with CT during a virtual simulation procedure.
Stereotactic body radiotherapy was performed by means of
TrueBeam with the RapidArc technique in 5 fractions of 6 Gy
with a cumulative dose of 30 Gy. The treatment was com-
pleted without acute side effects. In June 2011, at the ﬁrst
clinical and instrumental evaluation during follow-up, PET/CT
showed signiﬁcant reduction of FDG accumulation in the
treated area (see Fig. 1). No side effects were recorded. In
September 2011, a complete metabolic response was shown
at PET/CT and the same result of the absence of signs of
recurrence/persistence was conﬁrmed morphologically at the
last MRI  control in November 2011. During follow-up con-
trols, the otorhinolaryngologist detected a congestion and
thickening of the mucosa on the left side. With a mini-
mum follow-up of 9 months, the patient is free of relapse
and only moderate earache and sore throat were clinically
recorded.
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Fig. 1 – Case 1: Direct comparison of PET/CT axial images before and 6 months after the SBRT re-treatment (30 Gy in 5
rrenfractions), showing a complete response of nasophaynx recu
3.2.  Case  2
Male patient, 43 years old. In June 2009, metastases of carci-
noma were diagnosed during a neck level IIA–IIB dissection
after the ﬁrst negative nasopharynx biopsy. A subsequent
biopsy in the nasopharynx region conﬁrmed carcinoma of
Grade 2. MRI  showed multiple bilateral lymph node enlarge-
ment on Level II and an inﬁltration of the parapharyngeal
space on the left side. In July–August 2009, two cycles of TPF
chemotherapy was administered. Between September and
November 2009 the patient was submitted to radiotherapy:
56 Gy were delivered to the whole neck with a sequential
boost for a cumulative dose of 70 Gy to the rhinopharynx and
positive node involved in the neck bilaterally. Concomitant cis-
platin (100 mg/mq) was administered weekly. In January 2010,
MRI  showed a complete response. The patient was free from
Fig. 2 – Case 2: Direct comparison of PET/CT images before and 6
showing (with white arrows) a complete response in the site of nce.
recurrence until March 2011, when MRI evidenced patholog-
ical tissue on the nasopharynx on the left side toward the
nasal cavity. A nasal cavity biopsy conﬁrmed focal inﬁltra-
tion of nasopharynx carcinoma. In April 2011, the patient was
referred to our Department of Radiotherapy and Radiosurgery
and it was decided to re-irradiate the patient. PET/CT and MRI
were used as imaging tools for image  fusion with CT during a
virtual simulation procedure. Stereotactic body radiotherapy
was performed by means of TrueBeam with the RapidArc tech-
nique in 5 fractions of 6 Gy with a cumulative dose of 30 Gy.
The treatment was completed without acute side effects. In
May 2011, at the ﬁrst clinical and instrumental evaluation
during follow-up, PET/CT showed a signiﬁcant reduction of
FDG accumulation in the treated area in the posterior part
of the rhinopharynx region (see Fig. 2). Earache, lachryma-
tion increasing reduction of visual activity of the right eye
 months after the SBRT treatment (30 Gy in 5 fractions),
asophaynx relapse.
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ere recorded. A visit to the optometrist was recommended.
uring follow-up controls, the otorhinolaryngologist detected
ome crusting mucus on the roof of the nasopharynx that was
spirated. No suspicion of recurrence was found. In November
010, PET/CT showed a complete metabolic response. With a
inimum follow-up of 8 months the patient is free of relapse
nd only moderate earache and sore throat were clinically
ecorded.
.3. Case  3
ale patient, 53 years old. In March 2008, the patient com-
lained of diplopia and headache. In April 2008, MRI detected
n inﬁltration by neoplastic tissue in the clivus region towards
phenoidal bone and nasopharyngeal mucosa on the left side.
ith the suspicion of neoplasm of the clivus the patient
as submitted to a neurosurgery procedure to remove the
esion: the histological specimen revealed undifferentiated
arcinoma of the nasopharynx, related to EBV infection. Post-
urgical MRI  conﬁrmed residual tissue in the nasopharyngeal
ucosa and left latero-cervical lymph node (Level II) enlarge-
ent greater than 1 cm in diameter. Between May and August
008, three cycles of TPF chemotherapy were administered.
RI  showed stable disease and the patient was referred to the
adiation Oncology Department to undergo radical treatment
o the nasopharynx and pathological lymph node at II level
70 Gy) and precautional irradiation of the whole neck with
4 Gy. The treatment was not well tolerated and the patient
omplained of a high grade of mucositis with mucosal ulcer-
tion of the mouth. In January 2009, a complete response was
ound at MRI. In May 2009, the MRI  performed during follow-up
videnced inhomogeneous intensity signal for new tissue on
he upper part of the nasopharynx towards the pre-vertebral
egion. A biopsy performed in the suspicious region was neg-
tive and the patient was followed up with MRI to evaluate
he change in the suspicious tissue. Minimal progression was
ound in January 2010 but the patient refused treatment until
arch 2010 when three cycles of TPF-based chemotherapy
ere administered. In July 2010, a severe episode of epistaxis
ig. 3 – Case 3: Direct comparison of PET/CT axial images before 
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with tinnitus and anemization occurred needing hospitaliza-
tion. Desametasone was administered during support therapy
and a remission of symptoms was achieved after a few days.
In August 2010, MRI showed stable disease. PET/CT con-
ﬁrmed the disease with a pathological accumulation of FDG
on the nasopharynx, close to the temporal bone. In September
2010, the patient was referred to our Department of Radiother-
apy and Radiosurgery and, after a multidisciplinary discussion
with medical oncologists and head and neck surgeons, it was
decided to re-irradiate the patient. PET/CT and MRI  were uti-
lized as imaging tools for image  fusion with CT during a
virtual simulation procedure. A stereotactic body radiother-
apy was performed by means of TrueBeam with the RapidArc
technique in 5 fractions of 6 Gy with a cumulative dose of
30 Gy. After treatment, the patient complained of just a mild
headache and clinical situation was stable. At the ﬁrst clinical
and instrumental evaluation during follow-up in December
2010, PET/CT showed a complete metabolic response in the
treated area (see Fig. 3). This pattern of the absence of disease
was conﬁrmed at MRI after three months. The patient was
free from failure during instrumental and clinical evaluation
for 14 months until an episode of stroke cerebri. It was not pos-
sible to correlate this acute episode to the vascular damage of
previous local and systemic treatments.
3.4.  Case  4
Male patient 60 years old. In August 2005, nasopharyn-
geal carcinoma was diagnosed and treated with radical
radiochemotherapy: 70 Gy to the nasopharynx, 54 Gy to neck
bilaterally. Concomitant cisplatin (100 mg/mq) was adminis-
tered weekly. The patient was free from recurrence until March
2011 when MRI  detected lymph nodal enlargement of the
IB/IIA level on the right side of the neck, in the right parapha-
ryngeal region. Biopsy revealed nasopaharyngeal carcinoma.
In April 2011, PET conﬁrmed pathologic accumulation of FDG
in the same region. In May 2011, the patient was referred
to our Department of Radiotherapy and Radiosurgery and,
after a multidisciplinary discussion with medical oncologists
and after the SBRT treatment (30 Gy in 5 fractions), showing
266  reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 262–268
Fig. 4 – Case 4: Direct comparison of MRI  and PET/CT axial images performed before re-irriadiation (45 Gy in 18 fractions)
 the and after the re-treatment, showing a complete response in
and head and neck surgeons, it was decided to re-irradiate
the patient. PET/CT and MRI  were utilized as imaging tools
for image  fusion with CT during a virtual simulation proce-
dure. Hypofractionated radiotherapy was performed by means
of TrueBeam with the RapidArc technique in 18 fractions of
2.5 Gy with a cumulative dose of 45 Gy. The treatment was
well tolerated. Only mild dysphagia was reported. In August
2011, at the ﬁrst clinical and instrumental evaluation during
follow-up, MRI  showed a complete response in the treated area
(see Fig. 4). Otorhinolaryngologist evaluation was negative for
recurrence. In November 2011, PET/CT conﬁrmed a complete
metabolic response in the treated area. At the time of anal-
ysis, the patient was free from failure after 6 months from
reirradiation.
4.  Discussion
Radiation oncologists must consider several parameters
before prescribing retreatment with radiation. The feasibility
of reirradiation, especially in head and neck disease, depends
on previous doses and ﬁelds, the time between irradiation
and reirradiation, the general condition of the patient related
to life expectancy, and alternative treatment options. With
regard to dose tolerance in reirradiation, there is no consen-
sus about the dose limits to normal tissue involved in the
ﬁeld of previous radiotherapy. Concerning the current 4 cases,
for each patient a description of: (a) the dose delivered to
the nasopharynx during each course of RT, (b) the BED cal-
culation (biologically effective dose) for the different tissues
(˛/  ˇ = 15 for tumour; ˛/ˇ = 10 for acute response tissues as well
as mucosa; ˛/  ˇ = 4 for late responding tissues as well as nerves)
during each course of RT (c) the BED calculation of cumulative
doses for the two courses of RT, are shown in detail in Table 1.
The maintenance of functional activity in the pre-irradiatedirradiated lymph nodal site of recurrence.
ﬁeld should be an absolute priority.12 The few clinical data
available in the literature are extremely heterogeneous and
not only about head and neck district13–22: various techniques
(3-dimensional conformal radiotherapy, intraoperative radio-
therapy, brachytherapy, IMRT, stereotactic radiotherapy) were
reported in the same review; curative-intent and palliative
intent retreatments. Radiation side effects were also recorded
with various toxicity scales in different centers. The pre-
scribed retreatment doses are consequently decided upon on
a purely empirical basis. A cumulative toxicity risk evaluation
with the overlap of ﬁeld/isodose curves of the two treat-
ments or with the analysis of modern biological parameters,
if available, could be a way to minimize uncertainty regarding
toxicity. In three out of 4 of the presented cases we  decided
to prescribe an extreme hypofractionation as scheduled for
re-irradiation in the nasopharynx primary tumour region.
The choice of the prescription dose in hypofractionated
schedule with a high focused technique of radiotherapy, as
a stereotactic radiation therapy approach, was related also
to the paucity of experiences published recently on this
subject.21,23 However, a well known radiobiologic assumption
can support the approach of large dose per fraction in head
and neck retreatment with SBRT: the oral mucosa is an acute
responding tissue and it could be more damaged after a larger
cumulative dose (delivered for example by 1.8–2 Gy per frac-
tion) than in the cases when the cumulative dose is reduced
(delivered for example by 6 Gy per fraction).24 Compared to the
3 cases of extreme hypofractionation here reported, in case
4, lymph nodal recurrence was treated with a more careful
dosage of 45 Gy in 18 fractions. We  adopted the choice of a
moderate hypofractionation to avoid at maximum the dam-
age of cumulative doses of the two courses to soft tissues
and mucosa, in this case too close to other types of vari-
ous healthy tissues: carotid vessels, mandible and vertebral
bones, spine, parotid gland. Few data on the time interval
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 262–268 267
Table 1 – Description for each patient of: (a) the dose delivered to the nasopharynx during each course of RT, (b) the BED
calculation (biologically effective dose) for the different tissues(˛/  ˇ = 15 for tumour; ˛/  ˇ = 10 for acute response tissues as
well as mucosa; ˛/  ˇ = 4 for late responding tissues as well as nerves) during each course of RT (c) the BED calculation of
cumulative doses for the two courses of RT.
Case
number
Nominal dose in Gy
of the ﬁrst RT course
to the nasopharynx
region
BED of ﬁrst RT
course to the
nasopharynx
region
Nominal dose in Gy
of the second RT
course to the
nasopharynx region
BED of the second
RT course to the
nasopharynx
region
Cumulative BED of
the two  RT courses to
the nasopharynx
region
1 56  Gy + 9 Gy (boost)* * Not applicable 30 Gy 42(˛/ˇ = 15) * Not applicable
48(˛/ˇ = 10)
75(˛/ˇ = 4)
2 70 Gy 79(˛/ˇ  = 15) 30 Gy 42(˛/ˇ = 15) 112(˛/  ˇ = 15)
84(˛/ˇ = 10) 48(˛/ˇ = 10) 132(˛/  ˇ = 10)
105(˛/ˇ = 4) 75(˛/ˇ = 4) 180(˛/  ˇ = 4)
3 70 Gy 79.3(˛/  ˇ = 15) 30 Gy 42(˛/ˇ = 15) 112(˛/  ˇ = 15)
84(˛/ˇ = 10) 48(˛/ˇ = 10) 132(˛/  ˇ = 10)
105(˛/ˇ = 5) 75(˛/ˇ = 4) 180(˛/  ˇ = 4)
4 70 Gy 79(˛/ˇ  = 15) 45 Gy 42(˛/ˇ = 15) 112(˛/  ˇ = 15)
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ssue are available in the literature and most are from preclin-
cal analyses: the minimum interval between two radiation
reatments has not been clearly established. It might be con-
idered a sound approach to allow for an interval longer than
he period in which the most common late side effects would
e expected.23 This depends, however, on previous doses to
rgans at risk and the type of tissue damage repair. Com-
lete restoration of early radiation damage in some tissues,
uch as skin or oral mucosa, ranges from 12 to 90 days.2,23 For
ate damage, tissue recovery is variable and 5–6 months may
e necessary for many  tissue types, as reported in preclini-
al studies.25–27 In our four cases reported herein, a minimum
eriod of one year between prior radiotherapy and the new
ourse was guaranteed. Obviously, when the period is longer
han one year, the possibility of recovery from damage of the
revious treatment is higher making it more  possible to pre-
cribe more  effective doses and record less toxicity. The ideal
odalities of reirradiation involve other critical points, includ-
ng a better deﬁnition of the target to be reirradiated.28 In
ost cancer patients, PET/CT could be highly useful before
eirradiation for better deﬁnition of disease recurrence and
isease restaging.29 In all of the cases here presented, PET/CT
as performed during target deﬁnition and during follow-
p. Setup accuracy is another crucial point: immobilization
evices are essential to reduce setup errors.3 “Dose sculpt-
ng” on active tumor site with IMRT,  as volumetric modulation
rc therapy with the RapidArc technique of the four current
ases, is a helpful approach to minimize the radiation dose
o previously irradiated tissue.4,30,31 Image-guided radiation
herapy (IGRT) reduces repositioning errors and is used to
onitor the treatment region.3 TrueBeam is a platform for
dvanced radiotherapy that combines the RapidArc technique
nd IGRT by means of ConeBeam CTs, with the innovative
ossibility to deliver high doses per fraction in a few min-
tes. The capacity of TrueBeam to reduce treatment time is
elated to the FFF modality that allows the LINAC to perform dose rate four times greater than a classic beam. Reduction
f treatment time is crucial to reduce uncertainties of posi-
ioning during delivery, especially when very high doses per
raction are delivered close to organs at risk.5–9,32 Obviously,48(˛/ˇ = 10) 132(˛/  ˇ = 10)
75(˛/ˇ = 4) 180(˛/  ˇ = 4)
in re-irradiation, this can be even more  important. Consider-
ing the continuous advances in more  detailed cancer imaging
and safer radiation technology, promising clinical data, such
as the cases herein presented, suggesting new possibilities to
re-irradiate cancer patients in selected cases are still awaited.
Thus, cases of re-irradiation will be even more  usual for new
generation of Radiation Oncologists in the next few years and
they must be more  conscious about the risks of retreatments
but also on new potential weapon to face these challenging
situations.
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